Hepatocyte-Targeted Expression by Integrase-Defective Lentiviral Vectors Induces Antigen-Specific Tolerance in Mice with Low Genotoxic Risk

Lentiviral vectors are attractive tools for liver‐directed gene therapy because of their capacity for stable gene expression and the lack of preexisting immunity in most human subjects. However, the use of integrating vectors may raise some concerns about the potential risk of insertional mutagenesis. Here we investigated liver gene transfer by integrase‐defective lentiviral vectors (IDLVs) containing an inactivating mutation in the integrase (D64V). Hepatocyte‐targeted expression using IDLVs resulted in the sustained and robust induction of immune tolerance to both intracellular and secreted proteins, despite the reduced transgene expression levels in comparison with their integrase‐competent vector counterparts. IDLV‐mediated and hepatocyte‐targeted coagulation factor IX (FIX) expression prevented the induction of neutralizing antibodies to FIX even after antigen rechallenge in hemophilia B mice and accounted for relatively prolonged therapeutic FIX expression levels. Upon the delivery of intracellular model antigens, hepatocyte‐targeted IDLVs induced transgene‐specific regulatory T cells that contributed to the observed immune tolerance. Deep sequencing of IDLV‐transduced livers showed only rare genomic integrations that had no preference for gene coding regions and occurred mostly by a mechanism inconsistent with residual integrase activity. Conclusion: IDLVs provide an attractive platform for the tolerogenic expression of intracellular or secreted proteins in the liver with a substantially reduced risk of insertional mutagenesis. (HEPATOLOGY 2011;)

[1]  L. Steinman,et al.  Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity , 2010, Journal of internal medicine.

[2]  M. Banasik,et al.  Integrase-defective lentiviral vectors: progress and applications , 2010, Gene Therapy.

[3]  A. Annoni,et al.  In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. , 2009, Blood.

[4]  Luca Biasco,et al.  Comprehensive genomic access to vector integration in clinical gene therapy , 2009, Nature Medicine.

[5]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[6]  T. Kafri,et al.  Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection , 2009, Proceedings of the National Academy of Sciences.

[7]  R. Herzog,et al.  Gene therapy approaches to induce tolerance in autoimmunity by reshaping the immune system. , 2009, Current opinion in investigational drugs.

[8]  Christof von Kalle,et al.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.

[9]  R. Herzog,et al.  Hepatic gene transfer as a means of tolerance induction to transgene products. , 2009, Current gene therapy.

[10]  P. Desprès,et al.  Protective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine , 2008, PloS one.

[11]  Andrea Falini,et al.  Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. , 2008, Cancer cell.

[12]  W. Brück,et al.  Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. , 2008, The Journal of clinical investigation.

[13]  A. Annoni,et al.  A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. , 2007, Blood.

[14]  Hanno Glimm,et al.  High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.

[15]  Luis Apolonia,et al.  Stable gene transfer to muscle using non-integrating lentiviral vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Luigi Naldini,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[17]  P. Leone,et al.  Successful immunization with a single injection of non-integrating lentiviral vector. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  T. VandenDriessche,et al.  Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment , 2007, Journal of thrombosis and haemostasis : JTH.

[19]  J. Wilson,et al.  Efficacy and safety of adeno‐associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy , 2006, Journal of thrombosis and haemostasis : JTH.

[20]  J. Mallet,et al.  Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo , 2006, Proceedings of the National Academy of Sciences.

[21]  Xiao-Jin Yu,et al.  Transient gene expression by nonintegrating lentiviral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  L. Naldini,et al.  Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer , 2006, Nature Medicine.

[23]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[24]  S. E. Barker,et al.  Effective gene therapy with nonintegrating lentiviral vectors , 2006, Nature Medicine.

[25]  J. Prieto,et al.  IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  B. Rehermann,et al.  The liver as an immunological organ , 2004 .

[27]  N. Ferry,et al.  Liver gene therapy: advances and hurdles , 2004, Gene therapy.

[28]  V. Najfeld,et al.  Novel integrase-defective lentiviral episomal vectors for gene transfer. , 2004, Human gene therapy.

[29]  Daniel G. Miller,et al.  Adeno-associated virus vectors integrate at chromosome breakage sites , 2004, Nature Genetics.

[30]  J. Holmes,et al.  Unintegrated Lentivirus DNA Persistence and Accessibility to Expression in Nondividing Cells: Analysis with Class I Integrase Mutants , 2004, Journal of Virology.

[31]  Yuqin Wang,et al.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. , 2003, The Journal of clinical investigation.

[32]  L. Naldini,et al.  Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. , 2002, Blood.

[33]  W. J. Kent,et al.  BLAT--the BLAST-like alignment tool. , 2002, Genome research.

[34]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[35]  H. Varmus,et al.  Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection , 1996, Journal of virology.

[36]  J. Lau,et al.  Hepatology , 1999, Digestive Disease Interventions.

[37]  K. Brinkhous,et al.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. , 1953, The Journal of laboratory and clinical medicine.

[38]  D. Bellinger,et al.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. , 2009, ILAR journal.

[39]  L. Naldini,et al.  HIV-based vectors. Preparation and use. , 2002, Methods in molecular medicine.

[40]  M. Sahud.  Factor VIII inhibitors. Laboratory diagnosis of inhibitors. , 2000, Seminars in thrombosis and hemostasis.